Table 2.
Graft function outcomes of the r-ATG and basiliximab groups.
| Total (n = 268) |
Low Dose r-ATG (n = 37) |
Basiliximab (n = 231) |
p-Value | |
|---|---|---|---|---|
| DGF (%) | 2 (0.7) | 0 | 2 (0.9) | 0.898 |
| Graft failure (%) | 12 (4.5) | 1 (2.7) | 11 (4.8) | 0.737 |
| Patient death (%) | 3 (1.1) | 0 | 3 (1.3) | 0.657 |
| Total BPAR (%) | 125 (46.6) | 19 (51.4) | 106 (45.9) | 0.335 |
| Clinical BPAR | ||||
| TCMR (%) | 53 (19.8) | 4 (10.8) | 49 (21.2) * | 0.355 |
| Borderline change (%) | 29 (10.8) | 9 (24.3) | 20 (8.7) | |
| Subclinical BPAR † | ||||
| TCMR (%) | 11 (4.1) | 2 (5.4) * | 9 (3.9) * | |
| Borderline change (%) | 32 (11.9) | 4 (10.8) | 28 (12.1) | |
| No rejection | 143 (53.4) | 18 (48.6) | 125 (54.1) | |
| de novo DSA (total n = 245) ‡ | 10 (4.1) | 5 (14.3) | 5 (2.4) | 0.004 |
| e-GFR, mean (mL/min/1.73m2) | 0.120 | |||
| 1 month | 68.5 | 68.2 | 68.6 | |
| 1 year | 62.2 | 63.0 | 62.1 | |
| 2 years | 67.1 | 66.5 | 67.1 | |
| 3 years | 66.0 | 65.9 | 66.0 | |
| 5 years | 64.7 | 63.0 | 64.9 |
r-ATG, rabbit anti-thymocyte globulin; DGF, delayed graft function; BPAR, biopsy-proven acute rejection; TCMR, T-cell mediated acuter rejection; DSA, donor specific antibody; e-GFR, estimated-glomerular filtration rate; †: total 159 patients received protocol biopsy (34 and 125 in the r-ATG group and the basiliximab group, respectively); ‡: 35 and 210 patients were screened for de novo DSA in the r-ATG group and the basiliximab groups (2 and 21 patients omitted), respectively; *: Two patients had spontaneous AMR and clinical TCMR in the basiliximab group. Each one patient had spontaneous AMR and subclinical TCMR in the r-ATG and the basiliximab group.